Understand what your cancer types results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
When people hear "breast cancer biomarkers," they often think there might be a single blood test that can find or forecast breast cancer. That's not how this works. In breast cancer, biomarkers are a set of lab measurements on tumor tissue and sometimes blood that help define the biology of the cancer, estimate risk, and match treatment. Mammograms and MRIs are for screening. Biomarkers guide decisions after a diagnosis, and sometimes help monitor disease later. This guide walks you through what matters, what the major guidelines recommend, and what those results really mean.
What a biomarker does in breast cancer
Biomarkers fall into four practical buckets: diagnostic (classify the tumor), prognostic (estimate the chance of recurrence), predictive (estimate the chance a specific treatment will help), and monitoring (track disease activity over time). A good way to think about it is like tuning a fitness plan to your own physiology. The diagnosis is the starting point, but biomarkers personalize the plan, making sure the intensity matches your body's response.
The three core biomarkers every invasive breast cancer is tested for
Every invasive breast cancer should be tested for estrogen receptor (ER), progesterone receptor (PR), and HER2. This isn't optional: testing all three is recommended in early breast cancer because the results inform prognosis and guide access to therapies that can be life-saving.
ER and PR: Hormone receptors
What they are: Proteins on or in tumor cells that bind estrogen or progesterone. If present, the tumor is described as hormone receptor–positive (HR+).
How they're measured: Immunohistochemistry (IHC) on tumor tissue. Results are reported as a percentage of tumor cells staining and intensity. Even low-level ER positivity can matter, but most benefit is seen when a substantial fraction of cells express ER.
Why they matter: ER and PR positivity predicts tumor response to endocrine therapy, which lowers hormone signaling. That can be pills, injections, or ovarian suppression in premenopausal patients. It also gives prognostic information; HR+ cancers tend to have a longer natural history with late recurrences, which is why discussions about the duration of endocrine therapy exist.
HER2: A growth signaling receptor
What it is: A receptor that, when overexpressed or amplified, drives tumor growth. HER2 status divides breast cancer into two biologically distinct groups.
How it's measured: IHC for protein overexpression and, when equivocal, in situ hybridization (ISH) for gene amplification. Pathology reports use standardized scoring (0 to 3+). HER2-positive means IHC 3+ or ISH-amplified; HER2-negative means 0 or 1+, or 2+ with negative ISH.
Why it matters: HER2-positive disease is treated with HER2-targeted therapies and has improved dramatically with these drugs. A newer nuance is "HER2-low" (IHC 1+ or 2+ with negative ISH). While not "positive" in the classic sense, this category can be relevant for specific therapies in metastatic settings.
Limitations: Clinical interpretation depends on rigorous technique and experienced pathology. Bone biopsies that underwent acid decalcification may yield unreliable HER2 results. As with ER/PR, HER2 status can evolve—re-biopsy can correct course if results shift.
Ki-67 and proliferative markers: How clinicians read the speedometer
Ki-67 measures how quickly tumor cells are dividing. Higher values often correlate with more aggressive biology. In some specific settings, Ki-67 has helped identify which early HR+ patients have higher risk biology, and that prognostic signal holds even though scoring can be inconsistent across labs. Ki-67 is generally treated as supportive information rather than a stand-alone decision-maker, because of that interlaboratory variability. It can add color to the picture but rarely paints the whole canvas by itself.
Genomic assays for early-stage HR+/HER2− cancer: Who benefits from chemotherapy?
For many with early-stage, node-negative or limited node-positive HR+/HER2− breast cancer, the critical question is whether chemotherapy adds meaningful benefit on top of endocrine therapy. Multigene assays analyze patterns of tumor gene expression to estimate recurrence risk and potential chemotherapy benefit. They don't "diagnose" cancer—they refine risk and personalize therapy intensity.
Oncotype DX (recurrence score)
What it provides: A numerical score based on 21 genes that estimates 10-year distant recurrence risk and predicts chemotherapy benefit in HR+/HER2− early breast cancer.
Evidence: TAILORx showed that endocrine therapy alone is noninferior to chemoendocrine therapy in node-negative disease with a recurrence score of 11 to 25, though some chemotherapy benefit appeared in women 50 or younger with a score of 16 to 25. RxPONDER extended this picture to disease with one to three positive nodes and a score of 25 or lower, where chemotherapy benefit was confined to premenopausal women, with no added benefit in postmenopausal women. That's a key nuance—age and menopausal status, not just the numerical score, can change whether chemotherapy adds benefit.
How it's used: Routinely considered for stage I–II HR+/HER2− cancers and sometimes limited node-positive disease to guide adjuvant therapy planning.
Limitations: Not validated for HER2-positive or triple-negative cancers; results may be less informative if the tumor has peculiar histology or if tissue processing was suboptimal.
MammaPrint (70-gene), Prosigna (PAM50), EndoPredict, and breast cancer index
These assays share a purpose—refine risk and, in some cases, estimate the chance of late recurrence beyond five years. MammaPrint (MINDACT trial) helped identify patients with high clinical, low genomic risk who could safely forgo chemotherapy. Prosigna adds risk grouping that can stratify late recurrence risk out to 10 years in postmenopausal HR+/HER2− disease. EndoPredict and breast cancer index take a similar approach, focusing on two questions: risk of recurrence in years 5–10 and whether extended endocrine therapy might help. Each has its niche and evidence base; choice depends on clinical context, local availability, and guideline alignment.
Limitations: Assay outputs are not interchangeable. A "low risk" from one test does not automatically equal "low risk" from another. Results inform decisions but don't replace clinical judgment or patient preferences.
Germline genetic testing: Inherited risk and actionability
Germline testing looks for inherited variants that raise breast cancer risk and can change care for you and your family. It's different from tumor testing; this is DNA you were born with, typically from blood or saliva.
Who commonly meets criteria
Guidelines recommend offering BRCA1/2 testing to all newly diagnosed breast cancer patients 65 or younger, and to selected patients over 65 based on personal history, family history, ancestry, or eligibility for PARP-inhibitor therapy. Patients with recurrent disease who are candidates for PARP inhibitors should be offered testing regardless of family history. Many centers now use broader criteria because the results can change both treatment and prevention strategies.
Key genes and why they matter
- BRCA1 and BRCA2: Higher lifetime risks of breast and ovarian cancer; inform screening intensity, risk-reducing surgery discussions, and sensitivity to specific therapies like PARP inhibitors.
- PALB2: Risk nearly comparable to BRCA2 in some studies; affects screening and surgical planning.
- CHEK2 and ATM: Moderate risk genes that can shift screening strategies and inform family testing.
- TP53 (Li-Fraumeni syndrome): High risk of multiple cancers; impacts imaging choices due to radiation sensitivity and prompts tailored surveillance.
Limitations: A "variant of uncertain significance" is not actionable. Genetic counseling helps interpret results and plan next steps. A negative result in one person doesn't rule out risk in the family without testing an affected relative when possible.
Triple-negative breast cancer (TNBC): Immune and emerging biomarkers
TNBC lacks ER, PR, and HER2 amplification. Biology varies widely, which is why additional biomarkers can help.
PD-L1 expression
In metastatic TNBC, PD-L1 testing on tumor tissue can identify who is more likely to benefit from immunotherapy. Different assays and scoring systems exist (combined positive score vs. immune cell scoring), and not all are interchangeable. Early-stage immunotherapy decisions generally don't rely on PD-L1, but metastatic options often do.
Tumor-infiltrating lymphocytes (TILs)
TILs reflect the immune system's presence in the tumor. Higher TILs are associated with better outcomes in TNBC. While promising and prognostic, TILs are not widely used to change therapy on their own in routine practice.
Metastatic disease: Biomarkers for precision targeting
When breast cancer spreads, the biology can evolve. Re-biopsy of a metastatic site, when feasible, helps assess current ER, PR, and HER2 status. Beyond the basics, several actionable tumor alterations matter.
PIK3CA mutations
What they are: Mutations that activate the PI3K pathway in a significant fraction of HR+/HER2− metastatic cancers.
Why they matter: Presence of a PIK3CA mutation predicts benefit from a PI3K inhibitor combined with endocrine therapy. Testing can be done on tumor tissue or circulating tumor DNA (ctDNA); a positive result in ctDNA is informative, while a negative result can be a false negative if the tumor isn't shedding detectable DNA.
ESR1 mutations
What they are: Changes in the estrogen receptor gene that can drive resistance to aromatase inhibitors.
Why they matter: ESR1 mutations can be detected by ctDNA and may inform switching endocrine strategies, including consideration of agents that directly target or degrade the receptor.
HER2 mutations
Even when HER2 is not amplified, some tumors harbor activating HER2 mutations. These can predict sensitivity to specific HER2-targeted tyrosine kinase inhibitors in metastatic settings. Tumor sequencing or ctDNA can identify them.
BRCA and other homologous recombination repair genes
Germline BRCA1/2 variants and, in some cases, somatic alterations in DNA repair pathways can inform sensitivity to PARP inhibition in metastatic disease. This underscores why pairing germline and tumor testing can be complementary.
Rare but actionable fusions and high mutational burden
NTRK fusions are rare in breast cancer but, if present, open a path to targeted therapy. Tumor mutational burden and MSI-high status are uncommon here; when found, they may qualify for tumor-agnostic immunotherapy.
Liquid biopsy and ctDNA: What's ready, what's experimental
Liquid biopsy analyzes tumor DNA fragments circulating in the bloodstream. It's useful for detecting specific mutations like PIK3CA or ESR1 in metastatic disease, particularly when a tissue biopsy is hard to obtain. It can also help track the emergence of resistance mutations over time.
Serum tumor markers: CA 15-3, CA 27.29, and CEA
These are blood tests measuring proteins shed by tumor cells. They're not for screening or diagnosis. Guidelines caution against using them to detect cancer in people without symptoms because benign conditions, liver disease, and even pregnancy can elevate levels. In metastatic breast cancer, clinicians sometimes track these markers to follow trends in response to therapy. Rising markers alone shouldn't trigger a change in treatment without imaging or clinical correlation. Assays vary, and fluctuations can occur for reasons unrelated to tumor growth.
Breast density and risk models: Not treatment biomarkers, but useful context
Breast density is a radiologic feature that increases both cancer risk and the chance that a mammogram can miss a lesion. It's not a tumor biomarker, but it influences screening strategy. Risk models (like Tyrer–Cuzick) integrate age, family history, reproductive factors, and sometimes polygenic risk scores to estimate lifetime risk. These tools guide imaging choices such as adding MRI for higher-risk individuals. Polygenic risk scoring is promising yet still integrating into routine care—results should be used alongside, not instead of, clinical factors.
Life-stage and sex differences that influence biomarker use
- Premenopausal vs. postmenopausal: Genomic assays may yield similar numerical scores, but chemotherapy benefit can differ by menopausal status. RxPONDER found that chemotherapy benefit was confined to premenopausal patients with node-positive disease, with no added benefit for postmenopausal patients at the same recurrence score.
- Pregnancy: Serum tumor markers can physiologically rise, so they're not reliable. Imaging choices and timing of treatment are tailored; biomarker interpretation relies heavily on tissue testing rather than blood markers during pregnancy.
- Male breast cancer: More likely to be ER-positive. Germline testing yields actionable findings more often than in unselected female populations, so criteria for genetic evaluation are broad for men with breast cancer.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
How the tests are done: Practicalities that affect accuracy
Pathology and laboratory science details can change results. Good fixation of the surgical specimen, minimizing cold ischemia time, and using validated antibody clones and scoring systems are essential for accurate ER/PR/HER2 and Ki-67 results. For HER2, IHC 2+ triggers ISH testing to clarify amplification. For PD-L1, the assay used matters because different drugs validated different tests with distinct cutoffs.
For tumor sequencing, whether tissue was recently obtained and whether the sample has enough tumor content can affect detectability of mutations. Acid decalcification, which measurably lowers ER, PR, HER2, and Ki-67 immunohistochemistry scores, is a further reason bone specimens can be hard to work with. ctDNA tests need careful handling and rapid processing to preserve DNA fragments; a negative ctDNA result doesn't exclude a mutation if the tumor isn't shedding detectable DNA at that moment.
Putting it together: A typical pathway
At diagnosis after a core needle biopsy, the pathology report should include histologic type, grade, and ER/PR/HER2. If surgery is first, final pathology refines those findings and helps assess margins and nodal status. For HR+/HER2− early-stage disease, a genomic assay is often ordered to clarify the role of chemotherapy. If nodes are positive or disease is more advanced, the plan may include systemic therapy first, with biomarkers guiding choices and sequence.
During follow-up after curative treatment, routine imaging or blood tumor markers aren't recommended for asymptomatic patients; evidence shows they don't improve survival and can cause anxiety and false alarms. If cancer recurs or becomes metastatic, re-biopsy helps assess current ER/PR/HER2. Tumor sequencing or ctDNA can look for PIK3CA, ESR1, HER2 mutations, or rare fusions, which helps align therapy with the tumor's current behavior. Serum tumor markers, if used, track alongside scans and symptoms rather than replace them.
What results mean in real life
Biomarkers don't make decisions by themselves—people do. A patient with a low genomic risk score and a high-intensity career might prioritize avoiding chemotherapy's side effects and accept a very small increase in recurrence risk. Another might choose maximum therapy for peace of mind despite a low score. Biomarkers are guideposts. They improve the signal-to-noise ratio so decisions can be matched to biology and values.
Common misunderstandings, clarified
- "Is there a blood test to find breast cancer?" No. Mammography and MRI are screening tools. Serum tumor markers are not used to detect cancer in people without symptoms.
- "If my tumor marker is up, does that mean the cancer is growing?" Not necessarily. Infections, liver inflammation, and lab variation can nudge markers. Trends plus imaging are the gold standard for assessment.
- "My HER2 was negative the first time—does that ever change?" Yes. Tumor biology can evolve. Re-biopsy can uncover changes that open doors to new treatments.
- "If my genetic test is negative, does that mean my kids aren't at risk?" It depends. If no affected relative was tested, a negative in you may be less informative. Genetic counseling helps interpret what the result means for family members.
A note on quality, access, and equity
High-quality biomarker testing relies on standardized lab procedures and access to multidisciplinary care. Not every lab uses the same assays, and insurance coverage can be uneven for newer tests. If results seem out of step with your clinical picture—a HER2-negative result in a tumor behaving like HER2-positive, for example—asking the team about repeat testing or a second review is appropriate. This is not about second-guessing; it's about aligning care with accurate biology.
Credibility cues you can trust
- ER, PR, and HER2 testing in early breast cancer is recommended to inform prognosis and guide therapy selection.
- TAILORx and RxPONDER established how multigene assays can safely reduce chemotherapy use in many HR+/HER2− patients while preserving outcomes.
- MINDACT confirmed genomic risk can reclassify many clinically high-risk patients as candidates to avoid chemotherapy.
- Guideline recommendations support using tumor markers selectively, as an adjunct alongside imaging, to monitor metastatic disease rather than as a stand-alone basis for treatment decisions.
Bottom line
Biomarkers for breast cancer are not a single test; they're a toolkit. ER, PR, and HER2 define the broad strategy. Genomic assays in early HR+/HER2− disease refine who benefits from chemotherapy. Germline testing safeguards families and opens targeted options. In metastatic disease, tumor sequencing and ctDNA help track resistance and unlock precision therapies. Each test has strengths and limitations, and results must be interpreted in context. When used thoughtfully, biomarkers turn a one-size-fits-all diagnosis into a tailored plan that fits the biology of the cancer and the priorities of the person living with it.
Frequently Asked Questions
References
- Colomer R, González-Farré B, Ballesteros AI, et al (2024). Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. *Clin Transl Oncol*, *26*(12), 2935–2951.
- Wolff AC, Somerfield MR, Dowsett M, et al (2023). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *Arch Pathol Lab Med*, *147*(9), 993–1000.
- Clark BZ, Yoest JM, Onisko A, Dabbs DJ (2019). Effects of Hydrochloric Acid and Formic Acid Decalcification on Breast Tumor Biomarkers and HER2 Fluorescence In Situ Hybridization. *Appl Immunohistochem Mol Morphol*, *27*(3), 223–230.
- Probert J, Dodwell D, Broggio J, et al (2023). Ki67 and breast cancer mortality in women with invasive breast cancer. *JNCI Cancer Spectr*, *7*(5).
- Sparano JA, Gray RJ, Makower DF, et al (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med*, *379*(2), 111–121.
- Kalinsky K, Barlow WE, Gralow JR, et al (2021). 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. *N Engl J Med*, *385*(25), 2336–2347.
- Cardoso F, van't Veer LJ, Bogaerts J, et al (2016). 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med*, *375*(8), 717–29.
- Lænkholm AV, Jensen MB, Eriksen JO, et al (2018). PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. *J Clin Oncol*, *36*(8), 735–740.
- Bedrosian I, Somerfield MR, Achatz MI, et al (2024). Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. *J Clin Oncol*, *42*(5), 584–604.
- Cortes J, Cescon DW, Rugo HS, et al (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet*, *396*(10265), 1817–1828.
- Leon-Ferre RA, Jonas SF, Salgado R, et al (2024). Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. *JAMA*, *331*(13), 1135–1144.
- André F, Ciruelos E, Rubovszky G, et al (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med*, *380*(20), 1929–1940.
- Pascual J, Attard G, Bidard FC, et al (2022). ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*, *33*(8), 750–768.
- Gerratana L, Davis AA, Velimirovic M, et al (2023). Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis. *Breast Cancer Res*, *25*(1), 112.
- Ma CX, Bose R, Gao F, et al (2017). Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. *Clin Cancer Res*, *23*(19), 5687–5695.
- Wu S, Shi X, Ren X, Li K, Pang J, Liang Z (2021). Evaluation of NTRK Gene Fusion by Five Different Platforms in Triple-Negative Breast Carcinoma. *Front Mol Biosci*, *8*, 654387.
- Van Poznak C, Somerfield MR, Bast RC, et al (2015). Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*, *33*(24), 2695–704.
- Isautier JMJ, Houssami N, Hadlow C, et al (2024). Clinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwide. *JNCI Cancer Spectr*, *8*(6).
